To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Recruiting · NCT07303465 · Registry updated 2025-12-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. | KRAS G12D Mutations; Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | Phase 2 | 2025-12-24 | NCT07303465 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ranok Therapeutics (Hangzhou) Co., Ltd. | 4 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Nanjing Tianyinshan Hospital | Nanjing | China | 4 |
| Shanghai GoBroad Cancer Hospital China Pharmaccutical University | Shanghai | China | 1 |